MXPA04006575A - Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. - Google Patents
Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MXPA04006575A MXPA04006575A MXPA04006575A MXPA04006575A MXPA04006575A MX PA04006575 A MXPA04006575 A MX PA04006575A MX PA04006575 A MXPA04006575 A MX PA04006575A MX PA04006575 A MXPA04006575 A MX PA04006575A MX PA04006575 A MXPA04006575 A MX PA04006575A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- alzheimer
- substituted amino
- useful
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34531602P | 2002-01-04 | 2002-01-04 | |
| US35041902P | 2002-01-18 | 2002-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04006575A true MXPA04006575A (es) | 2004-10-04 |
Family
ID=26994342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04006575A MXPA04006575A (es) | 2002-01-04 | 2004-07-02 | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6962934B2 (https=) |
| EP (1) | EP1458745A2 (https=) |
| JP (1) | JP2005534614A (https=) |
| AU (1) | AU2003206413A1 (https=) |
| BR (1) | BR0306724A (https=) |
| CA (1) | CA2472617A1 (https=) |
| MX (1) | MXPA04006575A (https=) |
| WO (1) | WO2003057721A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1581510A4 (en) * | 2002-11-22 | 2006-08-30 | Bristol Myers Squibb Co | 1-ARYL-2-HYDROXYETHYLAMIDEALS CALIUM CHANNEL OPENER |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| CN100430377C (zh) * | 2003-06-30 | 2008-11-05 | 麦克公司 | 用于治疗阿尔茨海默病的N-烷基苯基甲酰胺β分泌酶抑制剂 |
| CA2543756A1 (en) * | 2003-10-30 | 2005-05-12 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer's disease |
| CA2548849A1 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| JP2007522129A (ja) * | 2004-01-21 | 2007-08-09 | エラン ファーマシューティカルズ，インコーポレイテッド | アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
| AU2005236063A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| WO2005103020A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2005113582A1 (en) * | 2004-05-22 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease |
| CA2570995A1 (en) * | 2004-06-15 | 2006-01-05 | Merck & Co., Inc. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| CA2603404A1 (en) * | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
| KR20080015079A (ko) | 2005-04-08 | 2008-02-18 | 코멘티스, 인코포레이티드 | 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법 |
| EP1915339A1 (de) * | 2005-08-11 | 2008-04-30 | Boehringer Ingelheim International GmbH | Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung |
| WO2007017510A2 (de) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Isophthalsäurediamide zur behandlung der alzheimer erkrankung |
| CA2618019A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for the treatment of alzheimer's disease |
| US20100144681A1 (en) * | 2005-08-11 | 2010-06-10 | Klaus Fuchs | Compounds for the treatment of alzheimer's disease |
| WO2007061670A1 (en) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Beta-secretase modulators and methods of use |
| US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
| US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
| US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
| US8163909B2 (en) | 2007-05-25 | 2012-04-24 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| CA2687608C (en) | 2007-05-25 | 2013-07-02 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| CA2687750C (en) | 2007-07-06 | 2016-10-18 | Boehringer Ingelheim International Gmbh | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture |
| US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
| CA2736130C (en) * | 2008-09-11 | 2014-01-14 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
| US9296698B2 (en) | 2009-11-23 | 2016-03-29 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| EP2504330A1 (en) | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| AU2011207679B2 (en) | 2010-01-19 | 2013-10-10 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| MX2012010657A (es) | 2010-03-15 | 2013-02-07 | Amgen Inc | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. |
| EP2547685A1 (en) | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
| EP2673279A1 (en) | 2011-02-07 | 2013-12-18 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
| WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| WO2014078314A1 (en) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362912A (en) | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
| US5552558A (en) | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| EP1302468B1 (en) | 1992-12-29 | 2008-12-17 | Abbott Laboratories | Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| US5942400A (en) | 1995-06-07 | 1999-08-24 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase |
| WO2000006559A1 (en) * | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Reduced dipeptide analogues as calcium channel antagonists |
| EP1192177A1 (en) * | 1999-06-15 | 2002-04-03 | Elan Pharmaceuticals, Inc. | Statine-derived tetrapeptide inhibitors of beta-secretase |
-
2003
- 2003-01-06 JP JP2003558035A patent/JP2005534614A/ja active Pending
- 2003-01-06 US US10/337,075 patent/US6962934B2/en not_active Expired - Fee Related
- 2003-01-06 BR BRPI0306724-6A patent/BR0306724A/pt not_active IP Right Cessation
- 2003-01-06 WO PCT/US2003/000326 patent/WO2003057721A2/en not_active Ceased
- 2003-01-06 CA CA002472617A patent/CA2472617A1/en not_active Abandoned
- 2003-01-06 EP EP03703711A patent/EP1458745A2/en not_active Withdrawn
- 2003-01-06 AU AU2003206413A patent/AU2003206413A1/en not_active Abandoned
-
2004
- 2004-07-02 MX MXPA04006575A patent/MXPA04006575A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US6962934B2 (en) | 2005-11-08 |
| EP1458745A2 (en) | 2004-09-22 |
| CA2472617A1 (en) | 2003-07-17 |
| JP2005534614A (ja) | 2005-11-17 |
| WO2003057721A2 (en) | 2003-07-17 |
| US20030166580A1 (en) | 2003-09-04 |
| WO2003057721A3 (en) | 2004-03-25 |
| AU2003206413A1 (en) | 2003-07-24 |
| AU2003206413A8 (en) | 2003-07-24 |
| BR0306724A (pt) | 2006-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04006575A (es) | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
| AP2004002952A0 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds. | |
| MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
| MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
| ATE326964T1 (de) | Aminosäurederivate zur behandlung der alzheimer- krankheit | |
| MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
| MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
| BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer | |
| WO2004029019A3 (en) | Compounds for the treatment of alzheimer’s disease | |
| WO2002094768A3 (en) | Aza hydroxylated ethyl amine compounds | |
| AU2002362008A1 (en) | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease | |
| WO2005042472A3 (en) | Hydroxypropyl amides for the treatment of alzheimer’s disease | |
| WO2004037179A3 (en) | Substituted peptides useful in the treatment of alzheimer’s disease | |
| ECSP044940A (es) | N-(3-amino-2-hidroxil-propil) compuestos substitutos de alquilamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |